AstraZeneca settles Nexium and Prilosec product liability litigations
AstraZeneca said Tuesday it has made agreements in the product liability litigations related to Nexium and Prilosec. The company said…
Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca said Tuesday it has made agreements in the product liability litigations related to Nexium and Prilosec. The company said…
Moderna announced Wednesday positive results from a clinical trial of mRNA-1083, its combination mRNA combination flu/COVID vaccine.
AIDS Healthcare Foundation (AHF) acknowledged today pharmaceutical company Johnson & Johnson’s (J&J) announcement that it will not enforce its patent for the multi-drug resistant tuberculosis treatment SIRTURO (bedaquiline) for 134 low- and middle-income countries—a significant step in ending the global TB crisis for a preventable, treatable, and curable disease.
Regeneron Pharmaceuticals and Sanofi have received U.S. Food and Drug Administration (FDA) acceptance for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat children aged 1 to 11 years with eosinophilic esophagitis (EoE).
ABRYSVO recommended by CDC Advisory Committee for pregnant persons 32 through 36 weeks gestation to help protect infants from respiratory…
AiCuris Anti-infective Cures AG has received milestone payments in the amount of EUR €30 million from its licensing partner MSD (Merck) after the U.S. FDA’s approval for first-in-class antiviral agent PREVYMIS® in a new indication – the prophylaxis of CMV disease after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients.
The data showed that tiragolumab plus Tecentriq was well-tolerated and no new safety signals were identified when adding tiragolumab to Tecentriq.
Redx has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) for Zelasudil, which is currently in a Phase 2a clinical study for IPF, with topline data expected in Q1 2024.
The Company to host an earnings conference call via webcast VICTORIA, British Columbia–(BUSINESS WIRE)–$IPA #AI–IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company”…
Launching in the fourth largest aesthetic toxin injectables market in Europe1 is part of the company’s geographic expansion strategy GP…